BridgeBio Pharma (NASDAQ:BBIO) CAO Sells $143,160.00 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CAO Maricel Apuli sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $71.58, for a total transaction of $143,160.00. Following the transaction, the chief accounting officer owned 134,115 shares in the company, valued at approximately $9,599,951.70. This trade represents a 1.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maricel Apuli also recently made the following trade(s):

• On Tuesday, February 17th, Maricel Apuli sold 510 shares of BridgeBio Pharma stock. The stock was sold at an average price of $74.31, for a total transaction of $37,898.10.

BridgeBio Pharma Price Performance

Shares of BBIO traded up $0.43 during mid-day trading on Monday, reaching $68.99. 1,886,949 shares of the company’s stock were exchanged, compared to its average volume of 2,751,298. The stock has a market capitalization of $13.51 billion, a PE ratio of -18.25 and a beta of 1.02. The business’s fifty day simple moving average is $71.28 and its 200-day simple moving average is $71.05. BridgeBio Pharma, Inc. has a 52-week low of $31.77 and a 52-week high of $84.94.

BridgeBio Pharma (NASDAQ:BBIO) last announced its earnings results on Tuesday, February 24th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.25). The firm had revenue of $154.18 million for the quarter, compared to analyst estimates of $150.71 million. The company’s revenue was up 2521.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.40) EPS. Equities research analysts predict that BridgeBio Pharma, Inc. will post -2.05 earnings per share for the current year.

Institutional Investors Weigh In On BridgeBio Pharma

Several hedge funds have recently modified their holdings of the stock. Principal Financial Group Inc. lifted its holdings in shares of BridgeBio Pharma by 1.2% during the first quarter. Principal Financial Group Inc. now owns 1,330,415 shares of the company’s stock worth $98,797,000 after purchasing an additional 16,112 shares during the period. Teachers Retirement System of The State of Kentucky lifted its holdings in shares of BridgeBio Pharma by 7.6% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 30,343 shares of the company’s stock worth $2,253,000 after purchasing an additional 2,132 shares during the period. Citizens Financial Group Inc. RI acquired a new stake in shares of BridgeBio Pharma during the first quarter worth $303,000. Fifth Third Bancorp acquired a new stake in shares of BridgeBio Pharma during the first quarter worth $3,693,000. Finally, Hsbc Holdings PLC lifted its holdings in shares of BridgeBio Pharma by 139.4% during the first quarter. Hsbc Holdings PLC now owns 32,708 shares of the company’s stock worth $2,431,000 after purchasing an additional 19,043 shares during the period. 99.85% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on BBIO. Morgan Stanley raised their target price on shares of BridgeBio Pharma from $96.00 to $98.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. TD Cowen restated a “buy” rating on shares of BridgeBio Pharma in a research report on Monday, January 12th. Oppenheimer lowered their target price on shares of BridgeBio Pharma from $83.00 to $81.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 25th. Wells Fargo & Company increased their price target on BridgeBio Pharma from $88.00 to $98.00 and gave the stock an “overweight” rating in a report on Friday, February 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BridgeBio Pharma in a report on Wednesday, January 21st. Twenty-four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, BridgeBio Pharma presently has a consensus rating of “Moderate Buy” and an average price target of $87.71.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.